The plasma fractionation market was valued at USD 28,605 million in 2022, and it is expected to reach a value of USD 50,638 million, growing at a rate of 7.4%, by 2030 as told in a report by P&S Intelligence.
 |
| To learn more about this report: https://bit.ly/42geiAh |
The growth of this industry is mainly driven by the increasing elderly populace, which is vulnerable to numerous rare disorders that formulate the requirement for plasma derivatives for treatment.
During the pandemic, the demand for convalescent plasma increased as it is required for patient treatment, thus advancing the industry growth.
The immunoglobulins category is expected to witness significant growth, at a rate of 7.9%, in the years to come. This is credited to the commercial availability of plasma-derived immunoglobulins and their increasing use, mainly for treating defects related to immune systems or chronic inflammatory demyelinating polyneuropathy patients.
North America held the largest revenue share of the industry, of approximately 55%. This is credited to the current development in the pharmaceutical research and development, the increasing number of plasma collection centers, rising paid plasma donation activities, the increasing population of hemophilic patients, growing product portfolios, and the existence of key players.
Moreover, Europe has the second-largest share of this industry. This is attributed to the increasing immunodeficiency and bleeding disorders, thus leading to increasing investments in these systems.
It is because of the increasing adoption of immunoglobulins in numerous therapies the expanding network of plasma collection facilities, and the growing incidence of respiratory problems, the plasma fractionation industry will experience considerable growth in the coming years.
